Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ValiRx plc ( (GB:VAL) ) just unveiled an announcement.
ValiRx PLC announced the termination of its Letter of Intent with TheoremRx Inc, which was initially extended until May 2025. The decision was mutual after TheoremRx chose not to amend the agreement regarding the territory of Taiwan. ValiRx plans to move its VAL201 asset into a special purpose vehicle focused on prostate cancer, with intentions to extend its patent life and explore new partnerships. This strategic shift aims to strengthen ValiRx’s position in the market, despite the setback with TheoremRx, by leveraging its technical expertise and seeking new collaborations.
More about ValiRx plc
ValiRx is a life science company focused on early-stage cancer therapeutics and women’s health. It accelerates the translation of innovative science into impactful medicines to improve patient lives. The company provides a framework for rapid translation of science into clinical development, selecting and incubating promising drug candidates and guiding them through development to become investor-ready assets. ValiRx collaborates with diverse disciplines to streamline the drug development process and outlicenses or partners lead candidates for further clinical development and commercialization. It is listed on the AIM Market of the London Stock Exchange.
YTD Price Performance: -39.10%
Average Trading Volume: 6,254,868
Technical Sentiment Signal: Buy
Current Market Cap: £1.87M
See more insights into VAL stock on TipRanks’ Stock Analysis page.